ValiRx Plc’s (VAL) “Corporate” Rating Reiterated at Northland Securities

Northland Securities reissued their corporate rating on shares of ValiRx Plc (LON:VAL) in a research note released on Tuesday.

Separately, Beaufort Securities restated a speculative buy rating on shares of ValiRx Plc in a report on Wednesday, September 14th.

Shares of ValiRx Plc (LON:VAL) opened at 8.25 on Tuesday. The company’s market cap is GBX 3.61 million. ValiRx Plc has a 1-year low of GBX 5.75 and a 1-year high of GBX 29.80. The company has a 50-day moving average price of GBX 7.39 and a 200-day moving average price of GBX 8.77.

About ValiRx Plc

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.